EN - Anglická CZ - Česká SK - Slovenská PL - Polská RO - Rumunská RU - Ruská TR - Turecká UA - Ukrajinská
EN - Anglická
  • CZ - Česká
  • SK - Slovenská
  • PL - Polská
  • RO - Rumunská
  • RU - Ruská
  • TR - Turecká
  • UA - Ukrajinská

Biocan Novel Respi nasal drops, lyophilisate and solvent for suspension for dogs

Homepage Products Veterinary products Biocan Novel Respi nasal drops, lyophilisate and solvent for suspension for dogs

To reduce clinical signs and bacterial excretion after infection with Bordetella bronchiseptica and to reduce clinical signs and viral excretion after infection with canine parainfluenza virus.

type of preparative: Vaccines
target species animals: Dog

Can we help you?

Statement of the active substances and other ingredients

Each dose of 0.5 ml contains:

Active substances:

Live attenuated Bordetella bronchiseptica strain MSLB 3096                              108.0–109.8 CFU*

Live attenuated Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15           103.5–105.8 CCID50**

*CFU: Colony forming unit
**CCID50: Cell culture infectious dose 50%

Solvent:

Water for injections (WFI)                                                                                      0.5 ml

Lyophilisate: spongy matter of whitish to yellowish colour.

Solvent: clear colourless liquid.

Indications

Active immunisation of dogs from 3 weeks of age:

  • to reduce clinical signs and bacterial excretion after infection with Bordetella bronchiseptica and
  • to reduce clinical signs and viral excretion after infection with canine parainfluenza virus.

Onset of immunity:

3 days after primary vaccination for Bordetella bronchiseptica.

7 days after primary vaccination for canine parainfluenza virus.

Duration of immunity:

1 year.

Contraindication

None.

Adverse reactions

Transient mild nasal discharge is very commonly, mild ocular discharge and mild depression are commonly and mild sneezing is uncommonly observed in animals after vaccination. These signs generally subside without treatment within one to three days. Mild to moderate coughing was commonly observed in vaccinated kenneled dogs from nine days after vaccination when housed together with non-vaccinated dogs.

Target species

Dogs.

Dosage for each species, route and method of administration

Nasal use.

Dosage of administration:

Primary vaccination scheme:

A single dose from 3 weeks of age.

Re-vaccination scheme:

A single dose to be given annually.

Advice on correct administration

Aseptically reconstitute the lyophilisate with the solvent. Shake well after reconstitution. Withdraw the liquid with the syringe, remove the needle and administer directly from the tip of the syringe into one nostril. Alternatively, an intranasal applicator (available separately) can be attached to the syringe and the dose then administered into one nostril. The vaccine should then be used immediately.

The head of the dog should be held with the nose pointing upwards. Administer one dose (0.5 ml) of the reconstituted vaccine into one nostril. 

Reconstituted vaccine: whitish to yellowish colour with a slight opalescence.

Withdrawal period

Not applicable.

Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C–8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

Use immediately after reconstitution.

Special warnings

Special warnings for each target species:

Vaccinate healthy animals only.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore, the use is not recommended during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

This product has been shown safe in dogs from 8 weeks of age when given at the same time as vaccines of the Biocan Novel ranges containing live canine parvovirus, adenovirus, distemper virus, parainfluenza virus as well as inactivated Leptospira and rabies virus. Mild (< 1 ºC), transient increases in temperature were very commonly observed following co-administration of these vaccines.

Incompatibilities:

Do not mix with any other veterinary medicinal product, except solvent supplied for use with the veterinary medicinal product.

Package

Transparent plastic box containing 5 vials of lyophilisate (one dose) and 5 vials of solvent (0.5 ml).

Transparent plastic box containing 10 vials of lyophilisate (one dose) and 10 vials of solvent (0.5 ml).

Not all pack sizes may be marketed.

Only for animals (dogs).

The veterinary medicinal product is available only on prescription.


Contact us


antispam
Please fill in the text displayed in the picture

or call


+420 517 318 598